Humaid Al-Shamsi: Balancing Evidence and Individualization in Adjuvant CDK4/6 Therapy
Humaid Al-Shamsi, Chief Executive Officer at Burjeel Cancer Institute and Regional Director of Burjeel Oncology GCC at Burjeel Holdings, shared a post on LinkedIn:
“Proud to share my 16th publication this year from Burjeel Cancer Institute (BCI) and 174th in my career: an editorial commentary co-authored with Professor Kefah Mokbel, published in Translational Cancer Research Journal.
In this commentary, we discuss the role of adjuvant CDK4/6 inhibitors in early breast cancer.
- Prof. Ian Tannock raises the concern that these drugs may result in over-treatment in some patients.
- Our view is that in appropriately selected high-risk patients, adjuvant CDK4/6 inhibitors should be offered, with decisions grounded in evidence, evolving guidelines, and patient values.
- The data announced for the MonarchE Trial Update (7-year follow-up, Lilly 2025): Two years of Verzenio (abemaciclib) + endocrine therapy significantly improved overall survival (OS) compared to endocrine therapy alone in HR+, HER2-, node-positive, high-risk early breast cancer.
Durable benefit in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) confirmed long-term efficacy.
This new OS data—unavailable at the time our article went to print—directly supports our position that adjuvant abemaciclib saves lives in selected patients.
Read our editorial here.”
Title: Balancing evidence and individualization in adjuvant CDK4/6 therapy
Journal: Translational Cancer Research Journal
Authors: Humaid O. Al-Shamsi, Muharrem Oner, Kefah Mokbel
More posts featuring Humaid Al-Shamsi on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023